Premium
Chemotherapy of nonirradiated malignant gliomas. Phase II: Study of the combination of methyl‐CCNU, vincristine, and procarbazine
Author(s) -
Avellanosa Anthony M.,
West Charles R.,
Tsukada Yoshiaki,
Higby Donald J.,
Bakshi Surag,
Reese Peter A.,
Jennings E.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197909)44:3<839::aid-cncr2820440308>3.0.co;2-1
Subject(s) - procarbazine , medicine , vincristine , lomustine , leukopenia , glioma , chemotherapy , pyrimidinones , gastroenterology , oncology , cyclophosphamide , cancer research , chemistry , organic chemistry
Twenty‐eight adult patients with nonirradiated malignant gliomas of the brain were administered a combination of methyl‐CCNU (130 mg/m 2 , p.o., day 1), vincristine (2 mg/m 2 , i.v., day 1) and procarbazine (100 mg/m 2 , p.o., days 2 to 15) (MVP), scheduled to be given at successive 6 week intervals. Nineteen (67.9%) were not responsive to MVP and 9 (32.1%) were. Of 16 who had previous partial resection of their tumors, 8 (50%) responded to MVP and 8 (50%) did not. Of 12 who had previous biopsy, only 1 (8.3%) responded. Overall 1‐year survival rate for the 28 patients was 28.6%. Major side effects of MVP were leukopenia, thrombocytopenia, pulmonary emboli, and thrombophlebitis, detected mainly during the first 20 to 24 weeks of treatment.